Cyproterone Acetate (Androcur, BAY94-8367)

DRUG3 trials

Sponsors

Bayer, Tel-Aviv Sourasky Medical Center

Conditions

Blood CoagulationCoagulation FactorsGender Dysphoria, AdultHemostasisHypersexuality in MenProstate CancerSexual Deviations in MenSigns of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea

Unknown Phase

Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate

TerminatedNCT00919022

BayerProstate Cancer

Start: 2009-08-31End: 2011-08-31Updated: 2012-11-01

A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe

CompletedNCT04925180

BayerHypersexuality in Men, Prostate Cancer, Sexual Deviations in Men +1

Start: 2021-10-18End: 2021-12-31Updated: 2022-01-12

Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study

CompletedNCT07145281

Tel-Aviv Sourasky Medical CenterBlood Coagulation, Coagulation Factors, Gender Dysphoria, Adult +3

Start: 2022-11-10End: 2024-11-10Updated: 2025-08-28